Small-intestinal transplantation

Olivier Goulet, Dominique M. Jan, Nicole Brousse, Yan Revillon, Claude Ricour

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The management of patients with intestinal failure has benefited from progress in parenteral nutrition (PN), especially home-based PN. Intestinal transplantation is therefore possible and is now, in some conditions, the logical therapeutic option. Since 1985, more than 180 small-bowel grafts have been done, involving the isolated small bowel with or without the colon (38%), the liver-small bowel (46%) or several organs (16%). Two-thirds of recipients were under 20 years of age, and indications were short-bowel syndrome (64%), severe intractable diarrhoea (13%), abdominal cancer (13%) or chronic intestinal pseudo-obstruction syndrome (8%). Of the patients, 51% survived > 2 years after the graft. Patient and graft survival depends on the type of immunosuppression, i.e. cyclosporine or FK506. The results must be interpreted carefully as they represent the first experience in numerous centres using different immunosuppressive protocols, without any randomization. The results from the largest of these centres reflect the current situation more closely. Functional grafts lead to gastrointestinal autonomy (weaning of PN) while maintaining satisfactory nutritional status and normal growth in childhood. Intestinal transplantation is theoretically indicated for all patients permanently or dependent for a long time on PN. However, as PN is generally well tolerated, even for long periods, each indication for transplantation must be carefully weighed up in terms of the iatrogenic risk and quality of life. When PN has reached its limits, especially in those associated with vascular, infectious, hepatic or metabolic complications, intestinal transplantation must be undertaken. Transplantation of the small bowel alone remains the first option, as combined liver-small bowel grafting is only indicated in the case of life-threatening progressive cirrhogenic liver disease.

Original languageEnglish (US)
Pages (from-to)573-592
Number of pages20
JournalBailliere's Clinical Gastroenterology
Volume11
Issue number3
DOIs
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Parenteral Nutrition
Transplantation
Transplants
Liver
Home Parenteral Nutrition
Intestinal Pseudo-Obstruction
Short Bowel Syndrome
Tacrolimus
Graft Survival
Immunosuppressive Agents
Random Allocation
Weaning
Nutritional Status
Immunosuppression
Cyclosporine
Blood Vessels
Liver Diseases
Diarrhea
Colon
Quality of Life

Keywords

  • Acute graft rejection
  • Intestinal failure
  • Intestinal transplantation
  • Parenteral nutrition
  • Short-bowel syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Small-intestinal transplantation. / Goulet, Olivier; Jan, Dominique M.; Brousse, Nicole; Revillon, Yan; Ricour, Claude.

In: Bailliere's Clinical Gastroenterology, Vol. 11, No. 3, 09.1997, p. 573-592.

Research output: Contribution to journalArticle

Goulet, O, Jan, DM, Brousse, N, Revillon, Y & Ricour, C 1997, 'Small-intestinal transplantation', Bailliere's Clinical Gastroenterology, vol. 11, no. 3, pp. 573-592. https://doi.org/10.1016/S0950-3528(97)90032-4
Goulet, Olivier ; Jan, Dominique M. ; Brousse, Nicole ; Revillon, Yan ; Ricour, Claude. / Small-intestinal transplantation. In: Bailliere's Clinical Gastroenterology. 1997 ; Vol. 11, No. 3. pp. 573-592.
@article{ba4bbc9b6efc4e08881516dcdccb4606,
title = "Small-intestinal transplantation",
abstract = "The management of patients with intestinal failure has benefited from progress in parenteral nutrition (PN), especially home-based PN. Intestinal transplantation is therefore possible and is now, in some conditions, the logical therapeutic option. Since 1985, more than 180 small-bowel grafts have been done, involving the isolated small bowel with or without the colon (38{\%}), the liver-small bowel (46{\%}) or several organs (16{\%}). Two-thirds of recipients were under 20 years of age, and indications were short-bowel syndrome (64{\%}), severe intractable diarrhoea (13{\%}), abdominal cancer (13{\%}) or chronic intestinal pseudo-obstruction syndrome (8{\%}). Of the patients, 51{\%} survived > 2 years after the graft. Patient and graft survival depends on the type of immunosuppression, i.e. cyclosporine or FK506. The results must be interpreted carefully as they represent the first experience in numerous centres using different immunosuppressive protocols, without any randomization. The results from the largest of these centres reflect the current situation more closely. Functional grafts lead to gastrointestinal autonomy (weaning of PN) while maintaining satisfactory nutritional status and normal growth in childhood. Intestinal transplantation is theoretically indicated for all patients permanently or dependent for a long time on PN. However, as PN is generally well tolerated, even for long periods, each indication for transplantation must be carefully weighed up in terms of the iatrogenic risk and quality of life. When PN has reached its limits, especially in those associated with vascular, infectious, hepatic or metabolic complications, intestinal transplantation must be undertaken. Transplantation of the small bowel alone remains the first option, as combined liver-small bowel grafting is only indicated in the case of life-threatening progressive cirrhogenic liver disease.",
keywords = "Acute graft rejection, Intestinal failure, Intestinal transplantation, Parenteral nutrition, Short-bowel syndrome",
author = "Olivier Goulet and Jan, {Dominique M.} and Nicole Brousse and Yan Revillon and Claude Ricour",
year = "1997",
month = "9",
doi = "10.1016/S0950-3528(97)90032-4",
language = "English (US)",
volume = "11",
pages = "573--592",
journal = "Bailliere's Clinical Gastroenterology",
issn = "0950-3528",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Small-intestinal transplantation

AU - Goulet, Olivier

AU - Jan, Dominique M.

AU - Brousse, Nicole

AU - Revillon, Yan

AU - Ricour, Claude

PY - 1997/9

Y1 - 1997/9

N2 - The management of patients with intestinal failure has benefited from progress in parenteral nutrition (PN), especially home-based PN. Intestinal transplantation is therefore possible and is now, in some conditions, the logical therapeutic option. Since 1985, more than 180 small-bowel grafts have been done, involving the isolated small bowel with or without the colon (38%), the liver-small bowel (46%) or several organs (16%). Two-thirds of recipients were under 20 years of age, and indications were short-bowel syndrome (64%), severe intractable diarrhoea (13%), abdominal cancer (13%) or chronic intestinal pseudo-obstruction syndrome (8%). Of the patients, 51% survived > 2 years after the graft. Patient and graft survival depends on the type of immunosuppression, i.e. cyclosporine or FK506. The results must be interpreted carefully as they represent the first experience in numerous centres using different immunosuppressive protocols, without any randomization. The results from the largest of these centres reflect the current situation more closely. Functional grafts lead to gastrointestinal autonomy (weaning of PN) while maintaining satisfactory nutritional status and normal growth in childhood. Intestinal transplantation is theoretically indicated for all patients permanently or dependent for a long time on PN. However, as PN is generally well tolerated, even for long periods, each indication for transplantation must be carefully weighed up in terms of the iatrogenic risk and quality of life. When PN has reached its limits, especially in those associated with vascular, infectious, hepatic or metabolic complications, intestinal transplantation must be undertaken. Transplantation of the small bowel alone remains the first option, as combined liver-small bowel grafting is only indicated in the case of life-threatening progressive cirrhogenic liver disease.

AB - The management of patients with intestinal failure has benefited from progress in parenteral nutrition (PN), especially home-based PN. Intestinal transplantation is therefore possible and is now, in some conditions, the logical therapeutic option. Since 1985, more than 180 small-bowel grafts have been done, involving the isolated small bowel with or without the colon (38%), the liver-small bowel (46%) or several organs (16%). Two-thirds of recipients were under 20 years of age, and indications were short-bowel syndrome (64%), severe intractable diarrhoea (13%), abdominal cancer (13%) or chronic intestinal pseudo-obstruction syndrome (8%). Of the patients, 51% survived > 2 years after the graft. Patient and graft survival depends on the type of immunosuppression, i.e. cyclosporine or FK506. The results must be interpreted carefully as they represent the first experience in numerous centres using different immunosuppressive protocols, without any randomization. The results from the largest of these centres reflect the current situation more closely. Functional grafts lead to gastrointestinal autonomy (weaning of PN) while maintaining satisfactory nutritional status and normal growth in childhood. Intestinal transplantation is theoretically indicated for all patients permanently or dependent for a long time on PN. However, as PN is generally well tolerated, even for long periods, each indication for transplantation must be carefully weighed up in terms of the iatrogenic risk and quality of life. When PN has reached its limits, especially in those associated with vascular, infectious, hepatic or metabolic complications, intestinal transplantation must be undertaken. Transplantation of the small bowel alone remains the first option, as combined liver-small bowel grafting is only indicated in the case of life-threatening progressive cirrhogenic liver disease.

KW - Acute graft rejection

KW - Intestinal failure

KW - Intestinal transplantation

KW - Parenteral nutrition

KW - Short-bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=0031437208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031437208&partnerID=8YFLogxK

U2 - 10.1016/S0950-3528(97)90032-4

DO - 10.1016/S0950-3528(97)90032-4

M3 - Article

VL - 11

SP - 573

EP - 592

JO - Bailliere's Clinical Gastroenterology

JF - Bailliere's Clinical Gastroenterology

SN - 0950-3528

IS - 3

ER -